Aurinia Pharmaceuticals
Late-stage biopharma developing therapies for serious diseases, including voclosporin for lupus nephritis, proteinuric diseases, and dry eye syndrome.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $200m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 15660 % | (9 %) | 194 % | 31 % | 34 % | 10 % | 19 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (192 %) | (392 %) | (83 %) | (36 %) | 23 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (205 %) | (397 %) | (81 %) | (44 %) | 2 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 100 % | 112 % | 34 % | 28 % | 9 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies to treat autoimmune diseases. The company primarily serves patients suffering from conditions such as lupus nephritis, a severe inflammation of the kidneys caused by systemic lupus erythematosus. Operating in the pharmaceutical market, Aurinia's business model revolves around research and development (R&D), clinical trials, and the subsequent commercialization of approved therapies. Revenue is generated through the sale of its flagship product, LUPKYNIS, which is designed to improve kidney function in lupus nephritis patients. The company also engages in strategic partnerships and licensing agreements to expand its market reach and enhance its product pipeline.
Keywords: biopharmaceutical, autoimmune diseases, lupus nephritis, LUPKYNIS, R&D, clinical trials, commercialization, kidney function, strategic partnerships, licensing.
Tech stack
Investments by Aurinia Pharmaceuticals
Edit